A Response to the Letter to the Editor: “Lazertinib Versus Osimertinib in EGFR-Mutant NSCLC: Efficacy, Toxicity, and Unaddressed Clinical Gaps”

Journal of Thoracic Oncology 2026

View at publisher

Authors: Se-Hoon Suk Lee, Shun Lu, James Chih-Hsin Yang, Sujay Shah, Seema Niphadkar Sethi, Byoung Chul Cho

DOI: 10.1016/j.jtho.2025.08.007

Cited by: 0

References: 9

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Chronic Myeloid Leukemia Treatments HER2/EGFR in Cancer Research

References 9